TGX

What this means for you

Not registered yet, but its 31 Jan 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79421844

Mark type

Stylized text

Filed

31 Jan 2025

Attorney of record

Alexandra MacKay

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical, medical or veterinary preparations and substances for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations and anti-neoplastic medicines for the treatment of neoplastic diseases; pharmaceutical preparations for the treatment of carcinomas and leukaemias; pharmaceutical preparations for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma and metastatic tumours; enhancers or super-enhancers for medical or clinical use, namely, engineered DNA; gene therapy products, namely, engineered DNA as synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; gene therapy pharmaceuticals for the treatment of neoplastic diseases, central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma, leukaemias and metastatic tumours; pharmaceutical preparations being viral vectors vaccines not for research purposes, namely, adenoviruses, adeno-associated viruses, poxviruses, reoviruses, lentiviruses and herpes simplex viruses; biotechnological preparations for medical use for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; biological compounds in the nature of genetically engineered DNA elements, viral vector for medical use, enzymes for medical purposes and cytokines being diagnostic chemical reagents for medical use for use in the targeted pharmaceutical therapies; protein arrays for medical diagnosis purposes with diagnostic and therapeutic uses; chemical and enzyme preparations for medical or veterinary purposes for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; clinical medical reagents and diagnostic reagents for use in testing for medical and veterinary purposes; drug delivery agents in the form of dissolvable films, tablets, capsules, powders, emulsions, injections, solutions and suspensions that facilitate the delivery of pharmaceutical preparations; clinical medical reagents; in vitro diagnostic and testing preparations for clinical, medical and medical laboratory use; pharmaceutical preparations in the field of modulating therapeutics; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; diagnostic biomarker reagents for medical purposes; cells for medical or clinical use; immune cells being cells for medical use; macromolecules bound to antibodies being target antigens for medical use; vaccine preparations; therapeutic vaccines
• Class 009 — Scientific and electric apparatus: Downloadable computer software programs for use in laboratory management systems and gene therapy platforms; downloadable software, namely, software for use with lab information management systems; downloadable computer software platforms for medical and scientific research; downloadable software for remote diagnostics; downloadable software using machine learning for analysing genomic data, designing gene therapy solutions and to assist with drug development; downloadable software using machine learning for use in genetic sequencing; algorithms, being downloadable computer software for use in designing genetic medicines and cancer immunotherapies; downloadable bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; downloadable data processing software; downloadable computer applications for use in the fields of oncology, recombinant protein production, immunology, cell engineering, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; downloadable software for predicting protein expression; downloadable software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, biochemical reagents and biochemical assays; downloadable computer software for scientific analysis of genetic sequences; downloadable software for creating optimization algorithms in the fields of biotechnology and modulating therapeutics; downloadable software as a medical device (SAMD), downloadable, for prevention, diagnosis, treatment, and monitoring of oncological diseases, genetic diseases, fibrosis and degenerative diseases; downloadable software using artificial intelligence for use in oncological, genetic and degenerative healthcare and in relation to fibrosis

Owner

• Trogenix Ltd, GB

Prosecution history

• 09 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 09 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 09 Sept 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
• 07 May 2026 — NEW REPRESENTATIVE AT IB RECEIVED
• 19 Apr 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
• 19 Apr 2026 — FINAL REFUSAL E-MAILED
• 19 Apr 2026 — FINAL REFUSAL WRITTEN
• 24 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 23 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 23 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 29 Nov 2025 — NEW REPRESENTATIVE AT IB RECEIVED
• 12 Sept 2025 — REFUSAL PROCESSED BY IB
• 25 Aug 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
• 25 Aug 2025 — REFUSAL PROCESSED BY MPU
• 22 Jul 2025 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW